SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Bindarit

Cat. No.: HY-B0498

CAS No.: 130641-38-2

Molecular Formula: $C_{19}H_{20}N_2O_3$

Molecular Weight: 324.37

Target: CCR

Pathway: GPCR/G Protein; Immunology/Inflammation

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 46 mg/mL (141.81 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	3.0829 mL	15.4145 mL	30.8290 mL
	5 mM	0.6166 mL	3.0829 mL	6.1658 mL
	10 mM	0.3083 mL	1.5414 mL	3.0829 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 50% PEG300 >> 50% saline
   Solubility: 5 mg/mL (15.41 mM); Clear solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.67 mg/mL (8.23 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.67 mg/mL (8.23 mM); Clear solution
4. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: 2.67 mg/mL (8.23 mM); Clear solution; Need warming

BIOLOGICAL ACTIVITY

Description

Bindarit (AF2838) is a selective inhibitor of the monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8, and no effect on other CC and CXC chemokines such as MIP-1α/CCL3, MIP-1β/CCL4, MIP-3/CCL23. Bindarit also has anti-inflammatory activity[1].

IC_{50} & Target	MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8[1]
In Vitro	Bindarit (10-300 μM; 48 hours) at 100 μM and 300 μM significantly inhibits platelet derived growth factor-BB (PDGF-BB)-induced rat VSMCs proliferation by 27% and 42%, respectively[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay[1]

Cell Line:	VSMC cells
Concentration:	10 μM, 30 μM, 100 μM, 300 μM
Incubation Time:	48 hours
Result:	Inhibited PDGF-BB-induced rat VSMCs proliferation.

In Vivo	Bindarit (50 mg/kg; oral administration; every day; for 4 months, 6 months, 8 months; NZB/W F1 female mice) delays the onset of proteinuria and significantly protects from renal function impairment. Bindarit completely prevents monocyte chemoattractant protein (MCP-1) up-regulation[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NZB/W F1 female mice (two months of age)[2]
Dosage:	50 mg/kg
Administration:	Oral administration; every day; for 4 months, 6 months, 8 months
Result:	Delayed the onset of proteinuria and significantly protected from renal function impairment.

CUSTOMER VALIDATION

- Nat Nanotechnol. 2021 Jul;16(7):830-839.
- Materials Today. 2022.
- Cell Mol Immunol. 2023 Jun 12.
- Brain Behav Immun. 2020 Oct;89:400-413.
- Acta Pharm Sin B. 2024 Jun 26.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Grassia, G., et al., The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice. Cardiovasc Res, 2009. 84(3): p. 485-93.

[2]. Zoja C, Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int. 1998 Mar;53(3):726-34.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA